The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study - O'Brien, S; Burger, J A; Blum, K A (Blood (ASH Annual Meeting Abstracts), 2011)
et al.